Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F List

Showing results (101-110 of 212) with videos related to

Pageof 22
Sort By:
Blood|February 5, 2017
Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosisChetasi Talati, Ling Zhang, Ghada Shaheen, et al.
Leukemia Research|July 26, 2011
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literatureRahel A Mathew, John M Bennett, Jane Jijun Liu, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Haematologica|August 30, 2012
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndromeChristopher P Venner, Joanna Wegrzyn Woltosz, Thomas J Nevill, et al.
Leukemia Research|January 22, 2013
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification modelsVu H Duong, Jeffrey E Lancet, Ezzideen Alrawi, et al.
Annals of Hematology|November 24, 2017
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromesVu H Duong, Eric Padron, Najla H Al Ali, et al.
Leukemia Research|February 19, 2013
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLionel Adès, Mikkael A Sekeres, Alice Wolfromm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2012
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndromeAdam W Mailloux, Chiharu Sugimori, Rami S Komrokji, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2010
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Alan F List, David Cuthbertson, et al.
Pageof 22

Showing results (101-110 of 212) with videos related to

Sort By:
Pageof 22
Blood|February 5, 2017
Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosisChetasi Talati, Ling Zhang, Ghada Shaheen, et al.
Leukemia Research|July 26, 2011
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literatureRahel A Mathew, John M Bennett, Jane Jijun Liu, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Haematologica|August 30, 2012
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndromeChristopher P Venner, Joanna Wegrzyn Woltosz, Thomas J Nevill, et al.
Leukemia Research|January 22, 2013
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification modelsVu H Duong, Jeffrey E Lancet, Ezzideen Alrawi, et al.
Annals of Hematology|November 24, 2017
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromesVu H Duong, Eric Padron, Najla H Al Ali, et al.
Leukemia Research|February 19, 2013
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLionel Adès, Mikkael A Sekeres, Alice Wolfromm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2012
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndromeAdam W Mailloux, Chiharu Sugimori, Rami S Komrokji, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2010
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Alan F List, David Cuthbertson, et al.
Pageof 22